{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:46:22Z","timestamp":1791755182267,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with Alzheimer\u2019s disease (AD) and other dementias are more frequently exposed to polymedication, mainly due to the presence of comorbidities, are particularly vulnerable to drug-related problems, and present greater risk of adverse effects due to drug\u2013drug interactions (DDIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To assess the prevalence of clinically relevant interactions in dementia patients using a routine database, we describe the most frequent interactions and risk factors associated with them to facilitate specific interventions and programs to prevent and minimize them.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An observational, descriptive, and cross-sectional study that included patients with AD and other types of dementia (n = 100, 64% female) was conducted to identify potential DDI in their treatment using the Lexi-Interact\/Lexicomp\n                      <jats:sup>\u00ae<\/jats:sup>\n                      database.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 769 drugs were prescribed, involving 190 different active ingredients; 83% of the treatments included five or more drugs. DDI occurred in 87% of the patients, of which 63.2% were female. A total of 689 DDIs were found, grouped in 448 drug pairs, with a mean of 6.9 \u00b1 7.1 (range, 0\u201331) DDIs per patient, and 680 DDIs were considered clinically relevant. It was observed that 89.8% of the DDIs had a moderate level of severity, 23.5% had a good level of relevance, and pharmacodynamic-based DDIs accounted for 89.5%. The drugs most frequently involved in DDIs were quetiapine (24.5%) and acetylsalicylic acid (10%). A total of 97 DDIs were detected between the acetylcholinesterase inhibitors (AChEIs), and the remaining drugs were administered concomitantly. One of the most frequent DDIs was between AChEIs and beta-blocking agents (n = 29, 4.3%). The most important factors that showed the strongest association with the presence of drug interactions were the use of AChEIs (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.01) and the total number of drugs (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.014) taken by the patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with dementia present increased risk of DDIs. Among the most common drugs are psychotropic drugs, which are involved in pharmacodynamic interactions caused by the concomitant use of CNS-targeted drugs. The results highlight the difficulty to evaluate DDIs in clinical practice due to polymedication and variety of comorbidities. Therefore, it is important to review their treatment and consider metabolism inhibition or induction, and potentially P450 substrate overlapping.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1472932","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:46:09Z","timestamp":1730076369000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Patients with dementia: prevalence and type of drug\u2013drug interactions"],"prefix":"10.3389","volume":"15","author":[{"given":"Mar\u00eda Cristina","family":"Mu\u00f1oz-Contreras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"L\u00f3pez-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Segarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13041-022-00937-4","article-title":"Blood\u2013brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders","volume":"15","author":"Alajangi","year":"2022","journal-title":"Mol Brain. diciembre"},{"key":"B2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.anclin.2019.04.007","article-title":"Geriatric pharmacology: an update","volume":"37","author":"Andres","year":"2019","journal-title":"septiembre"},{"key":"B3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","article-title":"Hospitalisations and emergency department visits due to drug\u2013drug interactions: a literature review","volume":"16","author":"Becker","year":"2007","journal-title":"Pharmacoepidem Drug Safe"},{"key":"B4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","article-title":"Drug interactions in oncology","volume":"5","author":"Beijnen","year":"2004","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1941875210386491","article-title":"Neuroleptic malignant syndrome: a review for neurohospitalists","volume":"1","author":"Berman","year":"2011","journal-title":"Neurohospitalist. enero de"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.6061\/clinics\/2016(01)04","article-title":"Severe potential drug-drug interactions in older adults with dementia and associated factors","volume":"71","author":"Bogetti-Salazar","year":"2016","journal-title":"Clinics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12916-014-0192-4","article-title":"Comorbidity and dementia: a scoping review of the literature","volume":"12","author":"Bunn","year":"2014","journal-title":"BMC Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/00003088-200847050-00002","article-title":"Free drug metabolic clearance in elderly people","volume":"47","author":"Butler","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1532-5415.2004.52054.x","article-title":"The relationship between a dementia diagnosis, chronic illness, medicare expenditures, and hospital use","volume":"52","author":"Bynum","year":"2004","journal-title":"J Am. Geriatrics Soc. febrero de"},{"key":"B10","first-page":"213","article-title":"Interacciones de f\u00e1rmacos y sus implicaciones cl\u00ednicas. En: Fl\u00f3rez Farmacolog\u00eda","volume-title":"5","author":"De Cos","year":"2008"},{"key":"B11","doi-asserted-by":"publisher","first-page":"M173","DOI":"10.1093\/gerona\/57.3.m173","article-title":"Prevalence and impact of medical comorbidity in Alzheimer\u2019s disease","volume":"57","author":"Doraiswamy","year":"2002","journal-title":"Journals Gerontology Ser. A Biol. Sci. Med. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jns.2009.02.089","article-title":"Blood brain barrier: ageing and microvascular disease-systematic review and meta-analysis","volume":"283","author":"Farrall","year":"2009","journal-title":"J. Neurological Sci."},{"key":"B13","first-page":"90","article-title":"Consistency among two drug interaction compendia in onco-haematological inpatients","volume":"18","author":"Fern\u00e1ndez de Palencia Espinosa","year":"2016","journal-title":"Eur. J. Clin. Pharm. Aten. Farm"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1111\/jgs.17291","article-title":"Polypharmacy among older adults with dementia compared with those without dementia in the United States","volume":"69","author":"Growdon","year":"2021","journal-title":"J. Am. Geriatrics Soc."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00228-016-2084-3","article-title":"Drug-related hospital admissions among old people with dementia","volume":"72","author":"Gustafsson","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","article-title":"The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600 000 elderly patients from the Swedish prescribed drug register","volume":"30","author":"Johnell","year":"2007","journal-title":"Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3233\/JAD-170905","article-title":"Polypharmacy and potentially inappropriate medication in people with dementia: a nationwide study","volume":"63","author":"Kristensen","year":"2018","journal-title":"JAD"},{"key":"B18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/MLR.0b013e318178940b","article-title":"Implications of comorbidity on costs for patients with Alzheimer Disease","volume":"46","author":"Kuo","year":"2008","journal-title":"Med. Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2125.2010.03847.x","article-title":"Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment","volume":"71","author":"McLachlan","year":"2011","journal-title":"Brit Clinical Pharma. marzo"},{"key":"B21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s11095-014-1522-0","article-title":"Drug access to the central nervous system in Alzheimer\u2019s disease: preclinical and clinical insights","volume":"32","author":"Mehta","year":"2015","journal-title":"Pharm. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2147\/cia.s87466","article-title":"Potential drug-drug interactions in Alzheimer patients with behavioral symptoms","volume":"1457","author":"Monzani","year":"2015","journal-title":"Clin. Interv. Aging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"987936","DOI":"10.3389\/fpubh.2022.987936","article-title":"Role of caregivers on medication adherence management in polymedicated patients with Alzheimer\u2019s disease or other types of dementia","volume":"10","author":"Mu\u00f1oz-Contreras","year":"2022","journal-title":"Front. Public Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4155\/tde.10.41","article-title":"Transport of drugs across the blood-brain barrier in Alzheimer\u2019s disease","volume":"1","author":"Nicolazzo","year":"2010","journal-title":"Ther. Deliv."},{"key":"B25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/gps.4456","article-title":"Potentially inappropriate medications and drug-drug interactions in home-dwelling people with mild dementia: drug use in people with mild dementia","volume":"32","author":"Oesterhus","year":"2017","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B26","first-page":"1","article-title":"Drugs for the elderly. Second edition","volume":"71","author":"Offerhaus","year":"1997","journal-title":"WHO Reg. Publ. Eur. Ser."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"Cereb Blood Flow Metab noviembre"},{"key":"B28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/17425255.2017.1325873","article-title":"Pharmacokinetic and pharmacodynamic alterations in older people with dementia","volume":"13","author":"Reeve","year":"2017","journal-title":"Expert Opin. Drug Metabolism Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s2173-5085(09)70079-6","article-title":"Quality of interaction database management systems","volume":"33","author":"Rodr\u00edguez-Terol","year":"2009","journal-title":"Farm. Hosp."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0236830","DOI":"10.1371\/journal.pone.0236830","article-title":"Drug related problems in older adults living with dementia","volume":"15","author":"Ruangritchankul","year":"2020","journal-title":"PLoS ONE"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00228-018-2514-5","article-title":"Clinically relevant drug\u2013drug interactions among elderly people with dementia","volume":"74","author":"S\u00f6nnerstam","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1046\/j.1472-8206.2003.00193.x","article-title":"Metabolic drug interactions with new psychotropic agents","volume":"17","author":"Spina","year":"2003","journal-title":"Fundam. Clin. Pharma."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2165\/00002018-200730110-00005","article-title":"Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary)","volume":"30","author":"Tavassoli","year":"2007","journal-title":"Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40520-019-01420-2","article-title":"Mild polypharmacy and MCI progression in older adults: the mediation effect of drug\u2013drug interactions","volume":"33","author":"Trevisan","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2125.2006.02809.x","article-title":"Comparative assessment of four drug interaction compendia","volume":"63","author":"Vitry","year":"2007","journal-title":"Br Clin Pharmacol. junio"},{"key":"B37","unstructured":"Dementia"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1472932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:46:11Z","timestamp":1730076371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1472932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":37,"alternative-id":["10.3389\/fphar.2024.1472932"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1472932","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"article-number":"1472932"}}